☆ 4.7 Article

Immunogenicity and reactogenicity of homologous mRNA-based and vector-based SARS-CoV-2 vaccine regimens in patients receiving maintenance dialysis

CLINICAL IMMUNOLOGY (2022)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。

Review Urology & Nephrology

Review of Early Immune Response to SARS-CoV-2 Vaccination Among Patients With CKD

Edward J. Carr et al.

Summary: The effectiveness of SARS-CoV-2 vaccination in CKD patients, particularly transplant recipients and those receiving dialysis, varies in terms of antibody development rates. Further research is needed to evaluate the vaccine efficacy in these populations. Rigorous surveillance is crucial for early detection of potential adverse effects, especially for patients with autoimmune diseases and transplant recipients.

KIDNEY INTERNATIONAL REPORTS (2021)

添加到收藏夹

Article Infectious Diseases

A highly specific and sensitive serological assay detects SARS-CoV-2 antibody levels in COVID-19 patients that correlate with neutralization

David Peterhoff et al.

Summary: The study developed a specific and sensitive enzyme linked immunosorbent assay (ELISA) for detection of anti-SARS-CoV-2 antibody levels. The ELISA showed high specificity and strong correlation in detecting SARS-CoV-2 antibodies, and was able to generate robust antibody levels 10 days after symptom onset.

INFECTION (2021)

添加到收藏夹

Article Virology

Weak correlation between antibody titers and neutralizing activity in sera from SARS-CoV-2 infected subjects

Elena Criscuolo et al.

Summary: This study compared two serologic tests for SARS-CoV-2, showing an increase in sensitivity over time and high specificity. However, a poor direct correlation between antibody levels and neutralizing activity was observed. These findings highlight the importance of further research on antibody kinetics and the role of neutralizing antibodies for the development of effective vaccines.

JOURNAL OF MEDICAL VIROLOGY (2021)

添加到收藏夹

Article Urology & Nephrology

Humoral and Cellular Responses to mRNA-1273 and BNT162b2 SARS-CoV-2 Vaccines Administered to Hemodialysis Patients

Jose Jesus Broseta et al.

Summary: This study evaluated the humoral and cellular responses to mRNA SARS-CoV-2 vaccines in patients with kidney failure receiving maintenance dialysis. Results showed that a high proportion of patients developed humoral and cellular immune responses after vaccination, but older age and immunosuppressive treatment were associated with lower antibody levels.

AMERICAN JOURNAL OF KIDNEY DISEASES (2021)

添加到收藏夹

Article Biochemistry & Molecular Biology

Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses

Jordan R. Barrett et al.

Summary: The study demonstrates that a booster dose of ChAdOx1 nCoV-19 is safer and better tolerated than priming doses. The booster dose significantly enhances anti-spike neutralizing antibody titers and other functional antibody responses. These data support the two-dose vaccine regime currently being evaluated in phase 3 clinical trials.

NATURE MEDICINE (2021)

添加到收藏夹

Article Urology & Nephrology

The ROMANOV study found impaired humoral and cellular immune responses to SARS-CoV-2 mRNA vaccine in virus-unexposed patients receiving maintenance hemodialysis

Maxime Espi et al.

Summary: Patients on maintenance hemodialysis (MHD) show weakened immune responses after receiving two doses of mRNA vaccine, but those with a history of COVID-19 may benefit from a third vaccine injection based on their stronger response to the vaccine.

KIDNEY INTERNATIONAL (2021)

添加到收藏夹

Letter Urology & Nephrology

Waning humoral response 6 months after SARS-CoV-2 vaccination with the mRNA-BNT162b2 vaccine in hemodialysis patients: time for a boost

Tamara Davidovic et al.

KIDNEY INTERNATIONAL (2021)

添加到收藏夹

Review Urology & Nephrology

Systematic Review of Safety and Efficacy of COVID-19 Vaccines in Patients With Kidney Disease

Dorey A. Glenn et al.

KIDNEY INTERNATIONAL REPORTS (2021)

添加到收藏夹

Article Transplantation

Persistence of antibody response to SARS-CoV-2 in a cohort of haemodialysis patients with COVID-19

Suzanne Forbes et al.

Summary: HD patients have a strong and persistent antibody response after COVID-19 infection, with 95% developing antibodies and all maintaining antibody positivity for at least 148 days. Factors like age, duration of viral detection positivity, and symptoms influence the time to peak antibody response.

NEPHROLOGY DIALYSIS TRANSPLANTATION (2021)

添加到收藏夹

Article Transplantation

Haemodialysis patients show a highly diminished antibody response after COVID-19 mRNA vaccination compared with healthy controls

Benedikt Simon et al.

Summary: HD patients had significantly lower anti-SARS-CoV-2 S antibody titres compared to controls 21 days after vaccination. The HD group experienced fewer adverse events than the control group. There was no correlation between the antibody response to Hepatitis B vaccination and the SARS-CoV-2 vaccine.

NEPHROLOGY DIALYSIS TRANSPLANTATION (2021)

添加到收藏夹

Article Surgery

Cellular and humoral response after MRNA-1273 SARS-CoV-2 vaccine in kidney transplant recipients

David Cucchiari et al.

Summary: The study on 148 kidney transplant recipients showed that the mRNA SARS-CoV-2 vaccine elicited either cellular or humoral response in 65.0% of the patients. Approximately 20.9% of patients were considered to have prior immunization against SARS-CoV-2, while 79.1% were deemed naïve to the virus.

AMERICAN JOURNAL OF TRANSPLANTATION (2021)

添加到收藏夹

Article Urology & Nephrology

Early Humoral Responses of Hemodialysis Patients after COVID-19 Vaccination with BNT162b2

Claudius Speer et al.

Summary: Patients receiving long-term hemodialysis show a reduced antibody response to the first and second doses of the mRNA vaccine BNT162b2. The majority (82%) develop neutralizing antibodies after the second dose but at lower levels than healthy controls.

CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2021)

添加到收藏夹

Letter Urology & Nephrology

Antibody Response to COVID-19 Vaccination in Patients Receiving Dialysis

Shuchi Anand et al.

JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2021)

添加到收藏夹

Article Urology & Nephrology

Antibody Status, Disease History, and Incidence of SARS-CoV-2 Infection Among Patients on Chronic Dialysis

Dena E. Cohen et al.

Summary: Among ESKD patients, natural acquisition of anti-SARSCoV-2 IgG positivity is associated with a 45% lower risk of subsequent SARS-CoV-2 infection, and a 79% lower risk of clinically manifest COVID-19. Vaccine priority should be given to ESKD patients regardless of their COVID-19 history due to incomplete natural immunity.

JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2021)

添加到收藏夹

Editorial Material Urology & Nephrology

Immune response to SARSCoV-2 infection and vaccination in patients receiving kidney replacement therapy

T. Alp Ikizler et al.

Summary: This issue of Kidney International summarizes the initial experience regarding the immunogenicity of prior COVID-19 infection and the response to COVID-19 vaccines among patients on maintenance dialysis and kidney transplant recipients. Preliminary data suggest durability of immune response after COVID-19 infection, with a significant portion of dialysis patients developing robust antibody titers after the second vaccine dose, while kidney transplant recipients show a less-strong immune response.

KIDNEY INTERNATIONAL (2021)

添加到收藏夹

Letter Urology & Nephrology

Experience with SARS-CoV-2 BNT162b2 mRNA vaccine in dialysis patients

Noa Berar Yanay et al.

KIDNEY INTERNATIONAL (2021)

添加到收藏夹

Article Multidisciplinary Sciences

BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans

Ugur Sahin et al.

Summary: The BNT162b2 vaccine shows 95% efficacy in preventing COVID-19 by boosting neutralizing antibody titres and activating specific T cell responses. The vaccine-induced immune response is broad and stable, lasting for a prolonged period, providing good coverage against various SARS-CoV-2 variants.

NATURE (2021)

添加到收藏夹

Article Urology & Nephrology

Spike and neutralizing antibodies response to COVID-19 vaccination in haemodialysis patients

Matthieu Giot et al.

Summary: Most hemodialysis patients develop a strong humoral response to the SARS-CoV-2 vaccine, with neutralizing antibodies, showing potential protection against COVID-19. However, the long-term immunity and efficacy in preventing the disease still need further investigation.

CLINICAL KIDNEY JOURNAL (2021)

添加到收藏夹

Article Medicine, General & Internal

Evaluation of the SARS-CoV-2 Antibody Response to the BNT162b2 Vaccine in Patients Undergoing Hemodialysis

Kevin Yau et al.

Summary: The study indicates poor immunogenicity 28 days after a single dose of the BNT162b2 vaccine in the hemodialysis population, emphasizing the importance of following recommended vaccination schedules and not delaying the second dose in these at-risk individuals.

JAMA NETWORK OPEN (2021)

添加到收藏夹

Article Health Care Sciences & Services

Humoral and cellular immunity to SARS-CoV-2 vaccination in renal transplant versus dialysis patients: A prospective, multicenter observational study using mRNA-1273 or BNT162b2 mRNA vaccine

Julian Stumpf et al.

Summary: The study showed that dialysis patients had a high seroconversion rate after receiving the boost vaccination, while the majority of transplant recipients had impaired humoral responses. The type and number of immunosuppressive drugs, as well as the type of vaccine, were major determinants of seroconversion failure in both dialysis and transplant patients.

LANCET REGIONAL HEALTH-EUROPE (2021)

添加到收藏夹

Article Medicine, Research & Experimental

Impaired humoral and cellular immunity after SARS-CoV-2 BNT162b2 (tozinameran) prime-boost vaccination in kidney transplant recipients

Arne Sattler et al.

Summary: The study analyzed immune responses in kidney transplant recipients after receiving the BNT162b2 vaccine, finding weaker antibody responses in transplant patients compared to healthy individuals and most hemodialysis patients. Additionally, spike-specific T cell responses were significantly reduced in transplant patients, indicating a need for revised vaccination strategies in immunosuppressed individuals.

JOURNAL OF CLINICAL INVESTIGATION (2021)

添加到收藏夹

Review Immunology

Lessons for COVID-19 Immunity from Other Coronavirus Infections

Alan Sariol et al.

IMMUNITY (2020)

添加到收藏夹

Review Urology & Nephrology

The current and future landscape of dialysis

Jonathan Himmelfarb et al.

NATURE REVIEWS NEPHROLOGY (2020)

添加到收藏夹

Article Medicine, General & Internal

An mRNA Vaccine against SARS-CoV-2-Preliminary Report

L. A. Jackson et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

添加到收藏夹

Article Urology & Nephrology

Outcomes of patients with end -stage kidney disease hospitalized with COVID-19

Jia H. Ng et al.

KIDNEY INTERNATIONAL (2020)

添加到收藏夹

Article Medicine, General & Internal

Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates

Edward E. Walsh et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

添加到收藏夹

Article Urology & Nephrology

KDOQI Clinical Practice Guideline for Hemodialysis Adequacy: 2015 Update

John T. Daugirdas et al.

AMERICAN JOURNAL OF KIDNEY DISEASES (2015)

添加到收藏夹

Article Urology & Nephrology

CLINICAL PRACTICE GUIDELINES AND RECOMMENDATIONS ON PERITONEAL DIALYSIS ADEQUACY 2011

Peter G. Blake et al.

PERITONEAL DIALYSIS INTERNATIONAL (2011)

添加到收藏夹

Review Urology & Nephrology

Aspects of immune dysfunction in end-stage renal disease

Sawako Kato et al.

CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2008)

添加到收藏夹

Article Urology & Nephrology

Impaired Immune Responses and Antigen-Specific Memory CD4+ T Cells in Hemodialysis Patients

Nicolle Helena Renier Litjens et al.

JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2008)

添加到收藏夹

Article Immunology

Functional signatures in antiviral T-cell immunity for monitoring virus-associated diseases

G Pantaleo et al.

NATURE REVIEWS IMMUNOLOGY (2006)

添加到收藏夹

© Peeref 2019-2024. All rights reserved.